CD274 and breast carcinoma: Furthermore, recent studies have shown that DLAT expression is high in patients who exhibit resistance to anti-PD-L1/PD-1 treatments, implying that DLAT could serve as a predictive marker for breast cancer (BRCA) resistance to immunotherapy [62].